VALBIOTIS specializes in developing innovative nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. Its products are made for manufacturers in the agro-food and pharmaceutical industries. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.
Valbiotis has been listed on Euronext Growth since 7 June 2017.
- Label: Valbiotis
- Mnemonic: ALVAL
- ISIN code: FR 0013254851
- PEA-PME eligible: Oui
- Total number of shares: 3 647 072
- Institution: Portzamparc
- Analyst: Christophe Dombu
- Institution: Invest Securities
- Analysts: Martial Descoutures - Thibaut Voglimacci-Stephanopoli